1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Proton Pump Inhibitors (PPIs) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Proton Pump Inhibitors (PPIs) Market Revenue and Volume Forecast, by Drug Type
8.1.1. Esomeprazole
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Omeprazole
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Dexlansoprazole
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Pantoprazole
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast
9.1. Proton Pump Inhibitors (PPIs) Market Revenue and Volume Forecast, by Route of Administration
9.1.1. Oral
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Injectable
9.1.2.1. Market Revenue and Volume Forecast
10.1. Proton Pump Inhibitors (PPIs) Market Revenue and Volume Forecast, by Indication
10.1.1. Gastroesophageal Reflux Disease
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Heartburn
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Peptic Ulcers
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast
11.1. Proton Pump Inhibitors (PPIs) Market Revenue and Volume Forecast, by Distribution Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Drug Stores
11.1.4.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Drug Type
12.1.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.3. Market Revenue and Volume Forecast, by Indication
12.1.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Drug Type
12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.5.3. Market Revenue and Volume Forecast, by Indication
12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Drug Type
12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.1.6.3. Market Revenue and Volume Forecast, by Indication
12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Drug Type
12.2.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.3. Market Revenue and Volume Forecast, by Indication
12.2.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Drug Type
12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.5.3. Market Revenue and Volume Forecast, by Indication
12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Drug Type
12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.6.3. Market Revenue and Volume Forecast, by Indication
12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Drug Type
12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.7.3. Market Revenue and Volume Forecast, by Indication
12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Drug Type
12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.2.8.3. Market Revenue and Volume Forecast, by Indication
12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Drug Type
12.3.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.3. Market Revenue and Volume Forecast, by Indication
12.3.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Drug Type
12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.5.3. Market Revenue and Volume Forecast, by Indication
12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Drug Type
12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.6.3. Market Revenue and Volume Forecast, by Indication
12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Drug Type
12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.7.3. Market Revenue and Volume Forecast, by Indication
12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Drug Type
12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.3.8.3. Market Revenue and Volume Forecast, by Indication
12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Drug Type
12.4.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.3. Market Revenue and Volume Forecast, by Indication
12.4.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Drug Type
12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.5.3. Market Revenue and Volume Forecast, by Indication
12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Drug Type
12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.6.3. Market Revenue and Volume Forecast, by Indication
12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Drug Type
12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.7.3. Market Revenue and Volume Forecast, by Indication
12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Drug Type
12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration
12.4.8.3. Market Revenue and Volume Forecast, by Indication
12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Drug Type
12.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.3. Market Revenue and Volume Forecast, by Indication
12.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Drug Type
12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.5.3. Market Revenue and Volume Forecast, by Indication
12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Drug Type
12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration
12.5.6.3. Market Revenue and Volume Forecast, by Indication
12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1. AstraZeneca
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bayer AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Cadila Pharmaceuticals
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Eisai Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GlaxoSmithKline PLC
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Takeda Pharmaceuticals
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Sanofi SA
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Dr. Reddy’s Laboratories
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Redhill Pharma Limited
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Cipla Limited
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client